Moleculin Biotech, Inc. Stockholders Equity

Quick Answer

Moleculin Biotech, Inc. reported Stockholders Equity of $15.01 million for fiscal year 2025.

Moleculin Biotech, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $15.01M +33.9%
2024 $11.21M -63.8%
2023 $30.93M -40.7%
2022 $52.19M -33.9%
2021 $78.99M +344.8%
2020 $17.76M +14.1%
2019 $15.57M +9.1%
2018 $14.27M -16.6%
2017 $17.12M +14.4%
2016 $14.96M +2108.1%
2015 -$745.0K

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 -$26.92M -254.6% -650.9%
June 30, 2025 -$3.58M -118.5% -126.0%
March 31, 2025 $13.79M -44.8% +23.0%
December 31, 2024 $11.21M -63.8% -35.6%
September 30, 2024 $17.41M -50.4% -10.3%
June 30, 2024 $19.41M -51.8% -22.3%
March 31, 2024 $24.99M -45.3% -19.2%
December 31, 2023 $30.93M -40.7% -12.0%
  • Moleculin Biotech, Inc. showed an increase of +33.9% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2015–2025 period, Moleculin Biotech, Inc.’s stockholders equity has grown by 2114.2% (from -$745.0 thousand to $15.01 million).
  • The most recent figure is from Moleculin Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment